weight loss information
|
New Weight Loss Drugs - Market PotentialPotential sales for weight loss obesity drug treatment are huge with an estimated worldwide clinically obese population of over 250 million. Treatment for obesity is a serious medical need, given it's effects on co-morbidities such as type 2 diabetes, heart disease, and high blood pressure. Some advanced weight loss drugs under development are Rimonabant from Sanofi-Synthelabo, ATL 962 from Alizyme, P 57 from Phytopharm, Axokine from Regeneron, and TAK 602 from Takeda. These drugs are under phase-3 trials and likely to reach the market in the next few years. Other new weight loss drugs in development include: Cholecystokinin (CCK) boosters (Astra Arcus, Glaxo-Wellcome), which prolongs the activity of CCK, a naturally occurring appetite suppressant. Neuropeptide Y (NYP) inhibitors (Neurogen, Pfizer, Synaptic Pharmaceuticals) block a potent chemical neurotransmitter that is an appetite stimulant. NPY inhibitors also enhance carbohydrate metabolism. Depending on the efficacy and safety profile of these drugs the weight loss obesity drugs market is expected to grow considerably over the next few years. Articles About Weight Loss Drugs |
|